Placebo to Aliskiren
Sponsors
Novartis, Novartis Pharmaceuticals
Conditions
Essential HypertensionHeart FailureHypertensionNon-diabetic Nephropathy
Phase 2
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
CompletedNCT00819767
Start: 2009-02-28End: 2009-10-31Updated: 2011-06-28
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
CompletedNCT00923156
Start: 2009-05-31End: 2011-02-28Updated: 2012-07-26
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
TerminatedNCT01302899
Start: 2011-01-31End: 2011-12-31Updated: 2013-01-30
Phase 3
Phase 4
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
CompletedNCT00631917
Start: 2008-02-29End: 2009-09-30Updated: 2011-07-12
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
CompletedNCT00654875
Start: 2008-03-31End: 2008-11-30Updated: 2011-06-28
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
CompletedNCT00865020
Start: 2009-03-31End: 2010-06-30Updated: 2011-07-22